Detection, significance and potential utility of circulating tumor cells in clinical practice in breast cancer (Review) DOI Open Access

Dominika Rusnáková,

Ramadan Aziri,

Peter Dubovan

et al.

Oncology Letters, Journal Year: 2024, Volume and Issue: 29(1)

Published: Oct. 17, 2024

Although advances in diagnostic techniques, new therapeutic strategies and personalization of breast cancer (BC) care have improved the survival for a number patients, BC remains major cause morbidity mortality women. The study circulating tumor cells (CTCs) has significant potential translational oncology since these represent promising biomarkers throughout entire course patients. CTCs also notable prognostic value early as well metastatic BC. Based on current knowledge, it seems that dynamics change during therapy reflect response, could serve tool risk stratification real-time monitoring treatment patients with question how to use this information everyday clinical practice can guide or affect outcome unanswered. present review aims discuss completed ongoing trials been designed demonstrate significance CTCs, offer insights into efficacy assess CTC utility, facilitating their implementation routine management

Language: Английский

Circulating tumor cells as liquid biopsy markers in cancer patients DOI Creative Commons
Daniel J. Smit, Klaus Pantel

Molecular Aspects of Medicine, Journal Year: 2024, Volume and Issue: 96, P. 101258 - 101258

Published: Feb. 21, 2024

Over the past decade, novel methods for enrichment and identification of cancer cells circulating in blood have been established. Blood-based detection other tumor-associated products can be summarized under term Liquid Biopsy. Circulating tumor (CTCs) used diagnosis, risk stratification treatment selection as well monitoring several studies over years, thus representing a valuable biomarker patients. A plethora to enrich, detect analyze CTCs has In contrast liquid biopsy analytes (e.g. ctDNA), represent viable analyte that provides unique opportunity understand underlaying biology metastatic cascade on molecular level. this review, we provide an overview current enrichment, detection, functional characterization CTCs.

Language: Английский

Citations

19
Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges DOI Open Access
Attila A. Seyhan

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(14), P. 7974 - 7974

Published: July 21, 2024

Gliomas, particularly glioblastoma (GBM), represent the most prevalent and aggressive tumors of central nervous system (CNS). Despite recent treatment advancements, patient survival rates remain low. The diagnosis GBM traditionally relies on neuroimaging methods such as magnetic resonance imaging (MRI) or computed tomography (CT) scans postoperative confirmation via histopathological molecular analysis. Imaging techniques struggle to differentiate between tumor progression treatment-related changes, leading potential misinterpretation delays. Similarly, tissue biopsies, while informative, are invasive not suitable for monitoring ongoing treatments. These challenges have led emergence liquid biopsy, through blood samples, a promising alternative monitoring. Presently, cerebrospinal fluid (CSF) sampling offers minimally means obtaining tumor-related information guide therapy. idea that any biofluid tests can be used screen many cancer types has huge potential. Tumors release various components into bloodstream other biofluids, including cell-free nucleic acids microRNAs (miRNAs), circulating DNA (ctDNA), cells (CTCs), proteins, extracellular vesicles (EVs) exosomes, metabolites, factors. factors been shown cross blood-brain barrier (BBB), presenting an opportunity well real-time assessment distinct genetic, epigenetic, transcriptomic, proteomic, metabolomic changes associated with brain tumors. their potential, clinical utility biopsy-based biomarkers is somewhat constrained by limitations absence standardized methodologies CSF collection, analyte extraction, analysis methods, small cohort sizes. Additionally, biopsies offer more precise insights morphology microenvironment. Therefore, objective biopsy should complement enhance diagnostic accuracy patients providing additional alongside traditional biopsies. Moreover, utilizing combination diverse biomarker may effectiveness compared solely relying one category, potentially improving sensitivity specificity addressing some existing GBM. This review presents overview latest research found in discusses diagnostic, predictive, prognostic indicators, future perspectives.

Language: Английский

Citations

13
Multibiomarker panels in liquid biopsy for early detection of pancreatic cancer – a comprehensive review DOI Creative Commons
Kim-Lea Reese, Klaus Pantel, Daniel J. Smit

et al.

Journal of Experimental & Clinical Cancer Research, Journal Year: 2024, Volume and Issue: 43(1)

Published: Sept. 2, 2024

Abstract Pancreatic ductal adenocarcinoma (PDAC) is frequently detected in late stages, which leads to limited therapeutic options and a dismal overall survival rate. To date, no robust method for the detection of early-stage PDAC that can be used targeted screening approaches available. Liquid biopsy allows minimally invasive collection body fluids (typically peripheral blood) subsequent analysis circulating tumor cells or tumor-associated molecules such as nucleic acids, proteins, metabolites may useful early diagnosis PDAC. Single biomarkers lack sensitivity and/or specificity reliably detect PDAC, while combinations these multimarker panels improve blood test-based diagnosis. In this narrative review, we present an overview different liquid discuss validity panels.

Language: Английский

Citations

7
The Combined Assessment of CTC and ESR1 Status in Liquid Biopsy Samples Enhances the Clinical Value of Prediction in Metastatic Breast Cancer DOI Open Access
Małgorzata Szostakowska-Rodzoś, Ewa A. Grzybowska, Izabella Myśliwy

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(5), P. 2038 - 2038

Published: Feb. 26, 2025

Monitoring of metastatic breast cancer (mBC) is an important issue in the clinical management patients. Liquid biopsy has become a non-invasive method for detecting and monitoring body fluids. The presence circulating tumor cells (CTCs) DNA (ctDNA) peripheral blood indicates poor prognosis may contribute to early detection progression, but assessment these levels still not routine management. main objective this study was estimate frequency value ESR1 PIK3CA mutations identified free (cfDNA.) second goal evaluate whether simultaneous evaluation CTCs mutation status cfDNA increases prognostic liquid biopsy. results analysis CTC number collected from 179 patients with show that are more frequent advanced luminal regardless type treatment. appear primarily during as no were found primary samples. conclusion combined improve

Language: Английский

Citations

0
Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model DOI Creative Commons
Daniel J. Smit, Thais Pereira‐Veiga,

H Bräuer

et al.

Molecular Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: March 25, 2025

Circulating tumor cells (CTCs) play an important role in metastasis formation. Aberrant signaling of oncogenic pathways (e.g., PI3K/AKT/mTOR pathway) drives progression. In this work, the susceptibility colon cancer CTC-derived cell line CTC-MCC-41 to AKT and mammalian target rapamycin (mTOR) inhibitors was evaluated. Additionally, functional expressed isoforms characterized line. The efficacy inhibitor MK2206, mTOR RAD001, combination examined a murine intracardiac xenotransplantation model. Furthermore, stable isoform-specific AKT1 or AKT2 knockdowns (KDs) as well AKT1/AKT2 double-KD were generated. Differentially regulated proteins phospho-peptides identified using liquid chromatography coupled mass spectrometry (LC-MS). showed high for dual targeting vivo, indicating that selective eradication CTCs by AKT/mTOR may be considered new treatment option cancer. KD significantly reduced proliferation cells. KDs share commonly phospho-proteins, but also regulate large number uniquely. show strongly dysregulated replication machinery, decrease cycle activity stem-cell-associated processes, underlining non-redundant isoforms.

Language: Английский

Citations

0
Cancer-associated fibroblasts as a potential novel liquid biopsy marker in cancer patients DOI Creative Commons

Franziska Weber,

Kim-Lea Reese, Klaus Pantel

et al.

Journal of Experimental & Clinical Cancer Research, Journal Year: 2025, Volume and Issue: 44(1)

Published: April 21, 2025

Abstract Cancer-associated fibroblasts (CAFs) are tissue residing cells within the tumor microenvironment (TME). Stromal CAFs have been shown to be associated with poor prognosis and progression in several solid entities. Although molecular mechanisms not fully understood yet, a critical role TME through direct interaction as well other has proposed. While most studies on focus stromal CAFs, recent reports highlight possibility of detecting circulating (cCAFs) blood. In contrast invasive biopsies for CAF characterization, liquid biopsy allows minimally isolation cCAFs. Furthermore, methods could enable continuous monitoring cCAFs cancer patients therefore may present novel biomarker tumors. this work, we an overview cCAF currently available summarize techniques detection. Moreover, future research directions emerging field highlighted potential applications biomarkers discussed.

Language: Английский

Citations

0
Circulating Extracellular Vesicles as Promising Biomarkers for Precession Diagnostics: A Perspective on Lung Cancer DOI

Sunil Vasu,

Vinith Johnson,

M Archana

et al.

ACS Biomaterials Science & Engineering, Journal Year: 2024, Volume and Issue: 11(1), P. 95 - 134

Published: Dec. 5, 2024

Extracellular vesicles (EVs) have emerged as promising biomarkers in liquid biopsy, owing to their ubiquitous presence bodily fluids and ability carry disease-related cargo. Recognizing significance disease diagnosis treatment, substantial efforts been dedicated developing efficient methods for EV isolation, detection, analysis. EVs, heterogeneous membrane-encapsulated secreted by all cells, contain bioactive substances capable of modulating recipient cell biology upon internalization, including proteins, lipids, DNA, various RNAs. Their prevalence across has positioned them pivotal mediators physiological pathological processes, notably cancer, where they hold potential straightforward tumor biomarkers. This review offers a comprehensive examination advanced nanotechnology-based techniques detecting lung cancer through It begins providing brief overview exosomes role progression. Furthermore, this explores the evolving landscape isolation cargo analysis, highlighting importance characterizing specific biomolecular signatures within EVs improved diagnostic accuracy patients. Innovative strategies enhancing sensitivity specificity integration microfluidic platforms multiplexed biosensing technologies are summarized. The discussion then extends key challenges associated with EV-based biopsies, such standardization detection protocols establishment robust analytical clinical translation. highlights transformative impact biopsy diagnosis, heralding new era personalized medicine patient care.

Language: Английский

Citations

2
Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells DOI Creative Commons
Daniel J. Smit,

H Bräuer,

Stefan Horn

et al.

Cellular Signalling, Journal Year: 2024, Volume and Issue: 121, P. 111270 - 111270

Published: June 21, 2024

In breast cancer, over one third of all patients harbor a somatic mutation in the PIK3CA gene, encoding p110α catalytic subunit phosphatidylinositol 3-kinase (PI3K) their tumor cells. Circulating cells (CTCs) are shed from primary into blood stream. Recently, long-term stable cancer CTC-ITB-01 cell line with tumorigenic and metastatic capacity was established liquid biopsy derived The oncogenic hotspot H1047R (kinase domain) detected tumor, CTCs metastasis same patient. Other mutations located within C2 domain (E418K E453K) were vaginal but not tumor. goal our study to functionally characterize impact rare E418K E453K that

Language: Английский

Citations

1
Lung cancer biomarkers: Raising the clinical value of the classical and the new ones DOI Creative Commons
Stefan Holdenrieder, Huub H. van Rossum, Michel M. van den Heuvel

et al.

Tumor Biology, Journal Year: 2024, Volume and Issue: 46(s1), P. S1 - S7

Published: March 19, 2024

Blood-based diagnostics for lung cancer support the diagnosis, estimation of prognosis, prediction, and monitoring therapy response in patients. The clinical utility serum tumor markers has considerably increased due to developments protein analytics biomarker studies, exploration preanalytical influencing conditions, interpretation combinations individual kinetics, as well implementation biostatistical models. In addition, circulating DNA (ctDNA) other liquid biopsy are playing an increasingly prominent role molecular characterization evolution over time. Thus, modern biomarkers may contribute individualized companion provide a sensitive guidance patients throughout course their disease. this special edition on Tumor Markers Lung Cancer, experts summarize recent laboratory give outlook future challenges opportunities.

Language: Английский

Citations

0
Pancreatic incidentaloma: incidental findings from history towards the era of liquid biopsy DOI Creative Commons
Matthias Löhr, Miroslav Vujasinović, Nikolaos Kartalis

et al.

eGastroenterology, Journal Year: 2024, Volume and Issue: 2(3), P. e100082 - e100082

Published: Sept. 1, 2024

This report provides an overview of the most common diagnostic methods that bring to light incidental findings pancreatic cancer. It reviews impact medical imaging and genetic assessment on definitions incidentaloma pancreas. For different approaches (eg, MRI CT) for affections (cysts/intraductal papillary mucinous neoplasia, solid lesions), specific guidelines have been proposed some are established. Based this, we summarise differences between traditional with those applied in PANCAID project. Biomarkers, predispositions, mutations circulating tumour cells give rise levels concern. The final part discusses risks opportunities associated further procedures surgical interventions. From ethical perspective, urging question is, can a screening based liquid biopsy blood samples open gateway prevention cancer-even if morbidity lethality today's interventions is still very high?

Language: Английский

Citations

0